These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26011686)

  • 1. Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans.
    Kielbasa W; Lobo E
    J Clin Pharmacol; 2015 Dec; 55(12):1422-31. PubMed ID: 26011686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition.
    Kielbasa W; Pan A; Pereira A
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):377-85. PubMed ID: 25637266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydroxyphenylglycol as a Biomarker of Norepinephrine Transporter Inhibition by Atomoxetine: Human Model to Assess Central and Peripheral Effects of Dosing.
    Bieck PR; Leibowitz M; Lachno DR; Ledent E; Padich R; Jhee S
    J Clin Psychopharmacol; 2016 Dec; 36(6):675-683. PubMed ID: 27755221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects.
    Chappell JC; Eisenhofer G; Owens MJ; Haber H; Lachno DR; Dean RA; Knadler MP; Nemeroff CB; Mitchell MI; Detke MJ; Iyengar S; Pangallo B; Lobo ED
    J Clin Psychopharmacol; 2014 Feb; 34(1):9-16. PubMed ID: 24346757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder.
    Kielbasa W; Quinlan T; Jin L; Xu W; Lachno DR; Dean RA; Allen AJ
    J Child Adolesc Psychopharmacol; 2012 Aug; 22(4):269-76. PubMed ID: 22849510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP-432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects.
    Sramek JJ; Hardy LW; Bieck P; Zamora C; Versavel M; Kharidia J; Grinnell T; Chen YL; Sullivan M; Ding H; Cutler NR
    CNS Neurosci Ther; 2016 May; 22(5):404-12. PubMed ID: 26849844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles.
    Vincent S; Bieck PR; Garland EM; Loghin C; Bymaster FP; Black BK; Gonzales C; Potter WZ; Robertson D
    Circulation; 2004 Jun; 109(25):3202-7. PubMed ID: 15184278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dialysate dihydroxyphenylglycol as a window for in situ axoplasmic norepinephrine disposition.
    Yamazaki T; Akiyama T; Kitagwa H; Kawada T; Sunagawa K
    Neurochem Int; 2001 Mar; 38(3):287-92. PubMed ID: 11099788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor.
    Kielbasa W; Tesfaye E; Luffer-Atlas D; Mitchell MI; Turik MA
    Eur J Clin Pharmacol; 2013 Dec; 69(12):2011-9. PubMed ID: 23955175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans.
    Goldstein DS; Eisenhofer G; Stull R; Folio CJ; Keiser HR; Kopin IJ
    J Clin Invest; 1988 Jan; 81(1):213-20. PubMed ID: 3335637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine.
    Montoya A; Escobar R; García-Polavieja MJ; Lachno DR; Alda JÁ; Artigas J; Cardo E; García M; Gastaminza X; Gilaberte I
    J Child Neurol; 2011 Jan; 26(1):31-6. PubMed ID: 20525942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma dihydroxyphenylglycol (DHPG) in the in vivo assessment of human neuronal norepinephrine metabolism.
    Izzo JL; Thompson DA; Horwitz D
    Life Sci; 1985 Sep; 37(11):1033-8. PubMed ID: 4033349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating dihydroxyphenylglycol and norepinephrine concentrations during sympathetic nervous system activation in patients with pheochromocytoma.
    Atuk NO; Hanks JB; Weltman J; Bogdonoff DL; Boyd DG; Vance ML
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1609-14. PubMed ID: 7989464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2.
    Moriguchi S; Takano H; Kimura Y; Nagashima T; Takahata K; Kubota M; Kitamura S; Ishii T; Ichise M; Zhang MR; Shimada H; Mimura M; Meyer JH; Higuchi M; Suhara T
    Int J Neuropsychopharmacol; 2017 Dec; 20(12):957-962. PubMed ID: 29016875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional extraction of circulating norepinephrine, DOPA, and dihydroxyphenylglycol in humans.
    Goldstein DS; Cannon RO; Quyyumi A; Chang P; Duncan M; Brush JE; Eisenhofer G
    J Auton Nerv Syst; 1991 Jun; 34(1):17-35. PubMed ID: 1940014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norepinephrine metabolism in neuron: dissociation between 3,4-dihydroxyphenylglycol and 3,4-dihydroxymandelic acid pathways.
    Dong WX; Ni XL
    Acta Pharmacol Sin; 2002 Jan; 23(1):59-65. PubMed ID: 11860739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LC-MS/MS method for quantification of 3,4-dihydroxyphenylglycol, a norepinephrine metabolite in plasma and brain regions.
    Padala NSP; Ajjala DR; Boggavarapu RK; Pantangi HR; Thentu JB; Mohammed AR; Nirogi R
    Bioanalysis; 2019 May; 11(10):971-986. PubMed ID: 31218903
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-Term, Open-Label, Safety Study of Edivoxetine Monotherapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Nery ESM; Bangs M; Liu P; Ahl J; Perahia D
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):700-707. PubMed ID: 28402139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on 3-methoxy-4-hydroxyphenylglycol (MHPG) and 3,4-dihydroxyphenylglycol (DHPG) levels in human urine, plasma and cerebrospinal fluids, and their significance in studies of depression.
    Tsuji M; Yamane H; Yamada N; Iida H; Taga C; Myojin T
    Jpn J Psychiatry Neurol; 1986 Mar; 40(1):47-56. PubMed ID: 3773351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Simultaneous liquid chromatographic determination of plasma 3,4-dihydroxyphenylglycol and norepinephrine as indicators of sympathetic activity].
    Okumura K; Ito T
    Nihon Naibunpi Gakkai Zasshi; 1990 Nov; 66(11):1164-9. PubMed ID: 2286283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.